Module 33 · ICU care & pharmacology

ICU pharmacology and drug infusions

NewPhase 1

Practical ICU pharmacology: standard infusion dilutions and rate maths for vasoactive, sedative and other common infusions, dosing in obesity, AKI/CRRT and augmented renal clearance, liver dysfunction, QT-prolonging drugs and key interactions, and IV compatibility and line safety.

6 topics

Drugs in this module

Doses written for this module's context. The same drug may read differently in another module.

Noradrenaline (norepinephrine)

Alpha-1 > beta-1 agonist vasopressor

Indications
First-line vasopressor in septic and most vasodilatory shock.
Adult dose
0.05-0.5 mcg/kg/min (higher in refractory shock); start ~0.05-0.1 mcg/kg/min titrated to MAP ≥ 65 mmHg.
Preparation (India)
2 mg/2 mL ampoules. Common syringe: 8 mg in 50 mL (160 mcg/mL) or 4 mg in 50 mL (80 mcg/mL) of NS or D5.
Cautions
Extravasation necrosis; peripheral use acceptable short-term via a good proximal vein with monitoring. Digital/mesenteric ischaemia at high doses.

Adrenaline (epinephrine)

Alpha and beta agonist

Indications
Second vasopressor/inotrope in shock; anaphylaxis infusion.
Adult dose
0.05-0.5 mcg/kg/min infusion.
Preparation (India)
1 mg/mL ampoules. Syringe: 4 mg in 50 mL (80 mcg/mL).
Cautions
Lactate rise (beta-2), tachyarrhythmia, hyperglycaemia.

Vasopressin

V1 receptor agonist

Indications
Add-on in septic shock when noradrenaline doses are escalating (commonly 0.25-0.5 mcg/kg/min; SSC 2026).
Adult dose
0.03 U/min fixed (up to 0.04 U/min); not weight-based.
Preparation (India)
20 U/mL 1 mL ampoules. Syringe: 20 U in 50 mL (0.4 U/mL); 0.03 U/min = 4.5 mL/h.
Cautions
Digital, mesenteric and myocardial ischaemia; hyponatraemia. Terlipressin is a different drug (bolus doses in mg), and SSC 2026 suggests against it in septic shock.

Dobutamine

Beta-1 agonist inotrope

Indications
Low cardiac output with adequate MAP and filling.
Adult dose
2.5-20 mcg/kg/min.
Preparation (India)
250 mg vials/ampoules (volume varies by brand). Syringe: 250 mg in 50 mL (5000 mcg/mL).
Cautions
Tachycardia, arrhythmia, hypotension from beta-2 vasodilatation.

Glyceryl trinitrate (nitroglycerin)

Nitrate venodilator

Indications
Hypertensive acute pulmonary oedema, ACS with ongoing pain or hypertension.
Adult dose
5-200 mcg/min titrated every 3-5 min (high-dose boluses used in SCAPE).
Preparation (India)
5 mg/mL ampoules (5 mL = 25 mg). Syringe: 50 mg in 50 mL (1 mg/mL = 1000 mcg/mL); 10 mcg/min = 0.6 mL/h.
Cautions
Hypotension in RV infarct or preload dependence; avoid within 24-48 h of PDE-5 inhibitors; PVC adsorption (use non-PVC sets).

Midazolam

Benzodiazepine

Indications
Sedation when propofol/dexmedetomidine unsuitable; status epilepticus.
Adult dose
Infusion 0.02-0.1 mg/kg/h (use lowest effective, daily interruption).
Preparation (India)
1 mg/mL (5 mL) and 5 mg/mL (1 mL, 10 mL) ampoules. Syringe: 50 mg in 50 mL (1 mg/mL).
Cautions
Accumulates in obesity, AKI (active metabolite) and liver failure; CYP3A4 inhibitors (azoles, macrolides) prolong effect; delirium.

Fentanyl

Synthetic opioid

Indications
Analgesia-first sedation in ventilated patients.
Adult dose
Infusion 0.5-2 mcg/kg/h (typical 25-150 mcg/h) dosed on ideal/adjusted weight in obesity.
Preparation (India)
50 mcg/mL in 2 mL and 10 mL ampoules. Syringe: 500 mcg in 50 mL (10 mcg/mL) or neat 50 mcg/mL.
Cautions
Context-sensitive accumulation with prolonged infusion and obesity; chest wall rigidity with rapid bolus; CYP3A4 interactions; serotonin syndrome with linezolid/SSRIs.

Propofol

GABA-A agonist hypnotic

Indications
Light sedation in ventilated patients; refractory status epilepticus.
Adult dose
5-50 mcg/kg/min (0.3-3 mg/kg/h); avoid > 4 mg/kg/h for > 48 h.
Preparation (India)
1% (10 mg/mL) 20 mL ampoules and 50 mL vials; run neat. 2% available.
Cautions
Hypotension; propofol infusion syndrome (acidosis, rhabdomyolysis, arrhythmia, hypertriglyceridaemia); lipid calories 1.1 kcal/mL; change giving set every 12 h (6-12 h for open vials).

Dexmedetomidine

Alpha-2 agonist

Indications
Light sedation, agitation/delirium, facilitation of NIV and extubation.
Adult dose
0.2-1.4 mcg/kg/h; loading doses usually omitted in ICU because of bradycardia/hypotension.
Preparation (India)
100 mcg/mL ampoules (1 mL, 2 mL). Syringe: 200 mcg in 50 mL (4 mcg/mL).
Cautions
Bradycardia, hypotension; does not provide deep sedation or amnesia.

Regular (soluble) insulin

Insulin

Indications
DKA/HHS, ICU hyperglycaemia > 180 mg/dL, hyperkalaemia.
Adult dose
DKA 0.1 U/kg/h (or 0.14 U/kg/h without bolus); ICU glucose by protocol targeting 140-180 mg/dL.
Preparation (India)
40 U/mL (U-40) and 100 U/mL vials. Syringe: 50 U in 50 mL NS (1 U/mL).
Cautions
U-40 vs U-100 confusion; adsorption to tubing (prime the line); hypokalaemia and hypoglycaemia.

Unfractionated heparin

Indirect thrombin/Xa inhibitor

Indications
Therapeutic anticoagulation where rapid reversal or AKI precludes LMWH; CRRT circuits.
Adult dose
VTE: 80 U/kg bolus then 18 U/kg/h (ACS: 60 U/kg max 4000 U, then 12 U/kg/h max 1000 U/h), adjusted to aPTT/anti-Xa.
Preparation (India)
5000 U/mL 5 mL vials (25,000 U). Syringe: 25,000 U in 50 mL (500 U/mL).
Cautions
Use actual weight with a cap per local nomogram in obesity; HIT; bleeding.

Amiodarone

Class III antiarrhythmic

Indications
AF with rapid ventricular response in haemodynamically fragile patients; VT; shock-refractory VF.
Adult dose
300 mg IV over 20-60 min, then 900 mg over 24 h.
Preparation (India)
150 mg/3 mL ampoules. Dilute in 5% dextrose; infusions > 2 mg/mL via central line; use in-line filter per product.
Cautions
Phlebitis peripherally; hypotension; QT prolongation (TdP uncommon); raises digoxin and warfarin effect.

Magnesium sulphate

Electrolyte / antiarrhythmic

Indications
Torsades de pointes; hypomagnesaemia; QT-risk mitigation.
Adult dose
TdP: 2 g IV over 1-2 min (pulseless) or 10-15 min; repeat or infuse 0.5-1 g/h.
Preparation (India)
50% w/v 2 mL ampoules (1 g = ~4 mmol).
Cautions
Hypotension with rapid infusion; accumulates in AKI (monitor levels and reflexes).

Vancomycin

Glycopeptide antibiotic

Indications
MRSA and other resistant Gram-positive infection.
Adult dose
Loading 20-35 mg/kg actual body weight (max ~3 g), then 15-20 mg/kg every 8-12 h adjusted to AUC 400-600 or trough levels.
Preparation (India)
500 mg and 1 g vials; infuse ≤ 10 mg/min (1 g over ≥ 1 h).
Cautions
Nephrotoxicity (especially with piperacillin-tazobactam), vancomycin infusion reaction with fast infusion.

Phentolamine

Alpha-adrenergic blocker

Indications
Extravasation of noradrenaline, adrenaline, dopamine or vasopressin.
Adult dose
5-10 mg diluted in 10 mL NS, infiltrated subcutaneously around the extravasation site within 12 h.
Preparation (India)
10 mg/mL ampoules – supply is irregular in India; keep in the ICU or know the alternative (topical nitroglycerin, SC terbutaline) per local policy.
Cautions
Hypotension, tachycardia.

Module references (12)

  1. 1

    Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509

  2. 2

    Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient – a focus on sedation, analgesia, and delirium. Crit Care. 2020;24:315

  3. 3

    Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother. 2000;34(9):1066-1069

  4. 4

    Matzke GR, Aronoff GR, Atkinson AJ, et al. Drug dosing consideration in patients with acute and chronic kidney disease – a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137

  5. 5

    Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011;7(9):539-543

  6. 6

    Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomized clinical trial. JAMA. 2024;332(8):629-637

  7. 7

    Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of β-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis. JAMA. 2024;332(8):638-648

  8. 8

    Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147-1161

  9. 9

    Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047-1060

  10. 10

    Kanji S, Lam J, Johanson C, et al. Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units. Crit Care Med. 2010;38(9):1890-1898

  11. 11

    Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581-585

  12. 12

    Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. 2026;52(5):863-936. Co-published in Crit Care Med. 2026 (doi:10.1097/CCM.0000000000007075)